Effectiveness of β lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis
- 31 January 2005
- Vol. 330 (7489) , 456
- https://doi.org/10.1136/bmj.38334.591586.82
Abstract
Objective To systematically compare β lactam antibiotics with antibiotics active against atypical pathogens in the management of community acquired pneumonia. Data sources Medline, Embase, Cochrane register of controlled trials, international conference proceedings, drug registration authorities, and pharmaceutical companies. Review methods Double blind randomised controlled monotherapy trials comparing β lactam antibiotics with antibiotics active against atypical pathogens in adults with community acquired pneumonia. Primary outcome was failure to achieve clinical cure or improvement. Results 18 trials totalling 6749 participants were identified, with most patients having mild to moderate community acquired pneumonia. The summary relative risk for treatment failure in all cause community acquired pneumonia showed no advantage of antibiotics active against atypical pathogens over β lactam antibiotics (0.97, 95% confidence interval 0.87 to 1.07). Subgroup analysis was undertaken in those with a specific diagnosis involving atypical pathogens. We found a significantly lower failure rate in patients with Legionella species who were treated with antibiotics active against atypical pathogens (0.40, 0.19 to 0.85). Equivalence was seen for Mycoplasma pneumoniae (0.60, 0.31 to 1.17) and Chlamydia pneumoniae (2.32, 0.67 to 8.03). Conclusions Evidence is lacking that clinical outcomes are improved by using antibiotics active against atypical pathogens in all cause non-severe community acquired pneumonia. Although such antibiotics were superior in the management of patients later shown to have legionella related pneumonia, this pathogen was rarely responsible for pneumonia within the included trials. β lactam agents should remain the antibiotics of initial choice in adults with non-severe community acquired pneumonia.Keywords
This publication has 34 references indexed in Scilit:
- Levofloxacin Efficacy in the Treatment of Community-Acquired LegionellosisChest, 2004
- Management of Patients with Community-acquired Pneumonia Treated in Hospital in SwedenScandinavian Journal of Infectious Diseases, 2002
- BTS Guidelines for the Management of Community Acquired Pneumonia in Adults.Published by Korean Cancer Association ,2001
- Practice Guidelines for the Management of Community-Acquired Pneumonia in AdultsClinical Infectious Diseases, 2000
- Associations Between Initial Antimicrobial Therapy and Medical Outcomes for Hospitalized Elderly Patients With PneumoniaArchives of internal medicine (1960), 1999
- Trovafloxacin versus high-dose amoxicillin (1 g three times daily) in the treatment of community-acquired bacterial pneumoniaEuropean Journal of Clinical Microbiology & Infectious Diseases, 1998
- Randomized, double-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia.Journal of Antimicrobial Chemotherapy, 1997
- Sparfloxacin versus cefaclor in the treatment of patients with community-acquired pneumonia: a randomized, double-masked, comparative, multicenter studyClinical Therapeutics, 1997
- Prediction of microbial aetiology at admission to hospital for pneumonia from the presenting clinical features. British Thoracic Society Pneumonia Research Subcommittee.Thorax, 1989
- The Treatment of Lobar Pneumonia and Pneumococcal Empyema with Penicillin.1944